News & Updates

Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.

Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.

Reduced lung function, regardless of smoking status, contributes to an increased hypertension prevalence, reports a study.

Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.

The addition of molnupiravir to usual care does not reduce hospitalization or death in vaccinated, community-dwelling individuals at high risk of serious outcomes of COVID-19, results of the UK-based PANORAMIC trial showed. However, it may provide other benefits such as reducing time to recovery.

Hypofractionated radiotherapy (HFRT) is not superior to conventionally fractionated radiotherapy (CFRT) in providing survival benefits to patients with stage I nonsmall cell lung cancer (NSCLC), but HFRT is preferable due to its convenience and lower costs, according to a study.